Jade Biosciences, Inc. (JBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has a cash flow conversion efficiency ratio of -0.099x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.66 Million) by net assets ($439.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see JBIO market cap for the company's overall valuation and market capitalisation.
Jade Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Jade Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jade Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jade Biosciences, Inc. ranked by their cash flow conversion efficiency. See Jade Biosciences, Inc. (JBIO) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Douglas Dynamics Inc
NYSE:PLOW
|
-0.082x |
|
Caisse Régionale de Crédit Agricole Mutuel de Paris et d-Ile-de-France
PA:CAF
|
0.025x |
|
Chengdu Hongqi Chain Co Ltd
SHE:002697
|
0.094x |
|
WUS Printed Circuit Co Ltd
TW:2316
|
-0.028x |
|
Chengdu Information Technology of Chinese Academy of Sciences Co Ltd
SHE:300678
|
0.047x |
|
Ningbo Runhe High-Tech Materials Co Ltd Class A
SHE:300727
|
0.057x |
|
Hangzhou Zhongtai Cryogenic Technology Corp
SHE:300435
|
0.067x |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
0.052x |
Annual Cash Flow Conversion Efficiency for Jade Biosciences, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Jade Biosciences, Inc. from 2020 to 2025. View Jade Biosciences, Inc. (JBIO) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.52 Million | $-94.69 Million | -0.285x | +69.43% |
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | +94.05% |
| 2020-12-31 | $2.94 Million | $-7.86 Million | -2.672x | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more